Drugs / NERIGLIATIN
last change Mar 2015 re-read 2 minutes ago

NERIGLIATIN

Small molecule targets GCK via activation

Developed for
type 2 diabetes mellitus
Investigated by
Pfizer

Trials 9 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT02292433 Jan → Mar 2015 type 2 diabetes mellitus Pfizer Completed No outcome recorded
Phase 1 NCT02206607 Sep 2014 → Jan 2015 type 2 diabetes mellitus Pfizer Completed No outcome recorded
Phase 1 NCT01933672 Oct 2013 → Mar 2014 type 2 diabetes mellitus Pfizer Completed No outcome recorded
Phase 1 NCT01513928 Jan → Feb 2012 Pfizer Completed No outcome recorded
Phase 1 NCT01468714 Oct 2011 Pfizer Completed No outcome recorded
Phase 1 NCT01272804 Feb → Jul 2011 type 2 diabetes mellitus Pfizer Completed No outcome recorded
Phase 1 NCT01044537 Feb → May 2010 type 2 diabetes mellitus Pfizer Completed No outcome recorded
Phase 22 trials
Phase 2 NCT01517373 Feb 2012 → Jan 2013 type 2 diabetes mellitus Pfizer Completed No outcome recorded
Phase 2 NCT01475461 Nov 2011 → Jan 2013 type 2 diabetes mellitus Pfizer Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as NERIGLIATIN ChEMBL registry synonym — accepted as the source's own label CHEMBL2165615
Known as N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide “The present article summarizes Metabolites in Safety Testing (MIST) studies on a glucokinase activator,...” PMID 25142735 Aug 2014
Known as Nerigliatina ChEMBL registry synonym — accepted as the source's own label CHEMBL2165615
Known as Nerigliatine ChEMBL registry synonym — accepted as the source's own label CHEMBL2165615
Known as PF04937319 “The purpose of this phase 1 study is to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF04937319 following single escalating oral doses in...” NCT01044537
9

NCT01272804

NCT02292433

NCT01475461

NCT01044537

NCT01517373

NCT01513928

NCT01933672

NCT02206607

NCT01468714

Action Activate “Hexokinase type IV activator” CHEMBL2165615
1

“a glucokinase activator” PMID 25142735 Aug 2014

Modality Small molecule CHEMBL2165615
Route Oral “All doses will be administered as a single oral dose as a powder-in-capsule (PIC) formulation.” NCT01044537
Target GCK “Hexokinase type IV activator” CHEMBL2165615